236,668 Shares in SPDR S&P Biotech ETF $XBI Purchased by Marks Wealth LLC

Marks Wealth LLC purchased a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 236,668 shares of the exchange traded fund’s stock, valued at approximately $28,857,000. SPDR S&P Biotech ETF comprises 9.7% of Marks Wealth LLC’s portfolio, making the stock its 6th biggest position. Marks Wealth LLC owned about 0.35% of SPDR S&P Biotech ETF at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XBI. AQR Capital Management LLC boosted its position in SPDR S&P Biotech ETF by 77.1% during the first quarter. AQR Capital Management LLC now owns 4,978 shares of the exchange traded fund’s stock worth $404,000 after acquiring an additional 2,167 shares during the last quarter. Marshall Wace LLP boosted its position in SPDR S&P Biotech ETF by 102.3% during the second quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock worth $334,000 after acquiring an additional 179,029 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in SPDR S&P Biotech ETF during the second quarter worth about $260,000. Ameriprise Financial Inc. boosted its position in SPDR S&P Biotech ETF by 123.0% during the second quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after acquiring an additional 481,408 shares during the last quarter. Finally, EP Wealth Advisors LLC boosted its position in SPDR S&P Biotech ETF by 3.7% during the second quarter. EP Wealth Advisors LLC now owns 5,379 shares of the exchange traded fund’s stock worth $446,000 after acquiring an additional 193 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

XBI opened at $130.42 on Monday. The firm has a market capitalization of $8.32 billion, a PE ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a twelve month low of $75.68 and a twelve month high of $139.19. The firm’s 50-day moving average price is $127.98 and its 200 day moving average price is $122.87.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.